ATE50983T1 - Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. - Google Patents
Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.Info
- Publication number
- ATE50983T1 ATE50983T1 AT86300037T AT86300037T ATE50983T1 AT E50983 T1 ATE50983 T1 AT E50983T1 AT 86300037 T AT86300037 T AT 86300037T AT 86300037 T AT86300037 T AT 86300037T AT E50983 T1 ATE50983 T1 AT E50983T1
- Authority
- AT
- Austria
- Prior art keywords
- omega
- dialkenoxy
- ntri
- dialkoxy
- alk
- Prior art date
Links
- 150000003868 ammonium compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- -1 piperidino, pyrrolidino Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Detergent Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68940785A | 1985-01-07 | 1985-01-07 | |
| EP86300037A EP0187702B1 (de) | 1985-01-07 | 1986-01-06 | Oberflächenaktive N-(omega, omega-1-Dialkoxy)- und N-(omega, omega-1-Dialkenoxy)-alk-1-yl-N,N,N-trisubstituierte Ammoniumverbindungen, deren Herstellung und sie enthaltende pharmazeutische Formulierungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE50983T1 true ATE50983T1 (de) | 1990-03-15 |
Family
ID=24768317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT86300037T ATE50983T1 (de) | 1985-01-07 | 1986-01-06 | Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0187702B1 (de) |
| JP (2) | JPH0662517B2 (de) |
| AT (1) | ATE50983T1 (de) |
| AU (1) | AU594654B2 (de) |
| CA (1) | CA1288774C (de) |
| DE (1) | DE3669503D1 (de) |
| NZ (1) | NZ214716A (de) |
| ZA (1) | ZA8681B (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| SE464448B (sv) * | 1985-04-04 | 1991-04-29 | Int Genetic Sciences | Fusogen fosfolipidvesikel innehaallande ett kvaternaert ammoniumhydroxidsalt i membranet samt ett foerfarande foer dess framstaellning |
| US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| DE4013632A1 (de) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| ES2089226T3 (es) * | 1990-09-06 | 1996-10-01 | Johnson & Son Inc S C | Procedimiento para estabilizar liposomas y composiciones que los contienen. |
| GB2250998A (en) * | 1990-12-21 | 1992-06-24 | Unilever Plc | Cosmetic cleansing composition |
| AU670818B2 (en) * | 1992-04-03 | 1996-08-01 | Cosmoferm B.V. | Selective N-acylation of amino alcohols |
| US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
| US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
| JPH07308570A (ja) * | 1994-05-16 | 1995-11-28 | Hirotaka Hirata | 界面活性物質を含む分子複合体 |
| EP0863749A2 (de) * | 1995-11-30 | 1998-09-16 | Vical Incorporated | Kationische lipide |
| DE19605175A1 (de) | 1996-02-13 | 1997-08-14 | Sourovoi Andrej Dr | Lipidverbindungen und deren Verwendung |
| EP0938298B1 (de) | 1996-09-13 | 2002-12-04 | Lipoxen Technologies Limited | Liposomenzusammensetzung |
| US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Life Technologies Corporation | Transfection reagents |
| CA2388301C (en) | 1999-10-22 | 2011-01-04 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| EP1792995A3 (de) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen |
| US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| EP1481268A4 (de) | 2002-02-07 | 2005-06-29 | Covalent Partners Llc | Nanofilm und membranzusammensetzungen |
| EP1356820A1 (de) | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen |
| JP2006273341A (ja) * | 2005-03-28 | 2006-10-12 | Toppan Printing Co Ltd | 乾燥能力インジケーター機能付蓋 |
| JP5072275B2 (ja) | 2006-07-03 | 2012-11-14 | テルモ株式会社 | 閉鎖小胞の分離方法、製剤の製造方法および評価方法 |
| WO2008054612A2 (en) | 2006-10-06 | 2008-05-08 | The Scripps Research Institute | Dna composition for eliciting an immune response against tumor-associated macrophages |
| JP5080779B2 (ja) | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
| WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| EP2411519B1 (de) | 2009-03-27 | 2015-07-22 | Institut National de la Santé et de la Recherche Médicale | Kanamycin-antisense-nucleinsäure zur behandlung von krebs |
| WO2011064790A1 (en) * | 2009-11-30 | 2011-06-03 | Avra Laboratories Pvt. Ltd | A novel process for making aliskiren, its novel intermediates and certain novel compounds |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| PL2547361T3 (pl) | 2010-03-17 | 2021-02-22 | Socpra - Sciences Et Génie, S.E.C. | Bakteryjne składniki szczepionek pochodzące ze staphylococcus aureus i ich zastosowania |
| US20130129811A1 (en) | 2010-04-28 | 2013-05-23 | Takeshi Kuboyama | Cationic lipid |
| KR101773643B1 (ko) | 2010-04-28 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 양이온성 지질 |
| CA2798837A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
| JP2013095755A (ja) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | カチオン性脂質 |
| JP6182457B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
| CN104159615B (zh) | 2011-12-12 | 2017-08-18 | 协和发酵麒麟株式会社 | 含有阳离子性脂质的组合的脂质纳米粒子 |
| PL2844282T3 (pl) | 2012-05-04 | 2019-11-29 | Pfizer | Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce |
| AU2013291125A1 (en) | 2012-07-16 | 2015-01-22 | Dicerna Pharmaceuticals, Inc. | RNAi pharmaceutical composition capable of suppressing expression of KRAS gene |
| US10195280B2 (en) | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP3362563A1 (de) | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy-nukleinsäuren für liposomale formulierung |
| US10525138B2 (en) | 2015-12-25 | 2020-01-07 | Kyowa Hakko Kirin Co., Ltd. | Compound as cationic lipid |
| CA2954892A1 (en) | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| JP7181208B2 (ja) | 2016-10-21 | 2022-11-30 | ソクプラ、サイエンシズ、エ、ジェニ、エス．イー．シー． | ワクチン構築物およびブドウ球菌感染症に対するその使用 |
| CN109996809A (zh) | 2016-11-14 | 2019-07-09 | 诺华股份有限公司 | 与促融合蛋白minion相关的组合物、方法和治疗用途 |
| IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
| IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
| CA3190696A1 (en) | 2020-08-28 | 2022-03-03 | Ke-He Ruan | Single-chain coronavirus viral membrane protein complexes |
| US20220185852A1 (en) | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
| CN116003271B (zh) * | 2022-12-13 | 2025-08-29 | 江西品信药业股份有限公司 | 一种季铵类脂质的合成方法 |
| WO2024200831A1 (en) | 2023-03-30 | 2024-10-03 | Vivadju | Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3567729A (en) * | 1968-01-12 | 1971-03-02 | Swift & Co | Diquaternary ammonium halides |
-
1986
- 1986-01-06 JP JP61001235A patent/JPH0662517B2/ja not_active Expired - Lifetime
- 1986-01-06 EP EP86300037A patent/EP0187702B1/de not_active Expired - Lifetime
- 1986-01-06 NZ NZ214716A patent/NZ214716A/xx unknown
- 1986-01-06 CA CA000499079A patent/CA1288774C/en not_active Expired - Lifetime
- 1986-01-06 AT AT86300037T patent/ATE50983T1/de not_active IP Right Cessation
- 1986-01-06 DE DE8686300037T patent/DE3669503D1/de not_active Expired - Lifetime
- 1986-01-06 AU AU51853/86A patent/AU594654B2/en not_active Expired
- 1986-01-06 ZA ZA8681A patent/ZA8681B/xx unknown
-
1994
- 1994-02-23 JP JP6025546A patent/JP2546623B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ZA8681B (en) | 1987-08-26 |
| JPH0770011A (ja) | 1995-03-14 |
| JPH0662517B2 (ja) | 1994-08-17 |
| NZ214716A (en) | 1989-04-26 |
| JPS61161246A (ja) | 1986-07-21 |
| DE3669503D1 (de) | 1990-04-19 |
| AU5185386A (en) | 1986-07-17 |
| CA1288774C (en) | 1991-09-10 |
| EP0187702A1 (de) | 1986-07-16 |
| EP0187702B1 (de) | 1990-03-14 |
| JP2546623B2 (ja) | 1996-10-23 |
| AU594654B2 (en) | 1990-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3669503D1 (de) | Oberflaechenaktive n-(omega, omega-1-dialkoxy)- und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,n-trisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. | |
| FR2662162B1 (fr) | Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. | |
| DE19875024I2 (de) | Amine Ihre verwendung und Herstellung | |
| NO942953D0 (no) | 11-benzaldoksimestradienderivater, fremgangsmåte for deres fremstilling smat legemddel inneholdende slike | |
| GR3018212T3 (en) | Naphtylalkylamines, process for their preparation and pharmaceutical compositions containing them. | |
| DE3372707D1 (en) | Spiro-(4,(3+n))-2-aza-alkan-3-carboxylic-acid derivatives, process for their preparation,agents containing them and their use | |
| FR2526659B1 (fr) | Medicaments immunomodulants a base de derives de l'acide phenylacetique | |
| IT1228288B (it) | Composti ad attivita' antiserotoninica | |
| ATE8144T1 (de) | Indolobenzoxazine, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen. | |
| AU576926B2 (en) | Tetrazole derivatives | |
| FR2597097B1 (fr) | Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique | |
| DE3752272D1 (de) | Verwendung eines Thioesters zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Ischämie und von Reperfusion-Syndromen | |
| HUT40553A (en) | Fungicides containing as active substance derivatives of imidasole and process for production of the active substance | |
| ATE56012T1 (de) | Indolo-(6,5,4-cd)-indol derivate und verfahren zu deren herstellung. | |
| IE41219L (en) | Aralkyl esters of aminoalkanoic acids | |
| FR2694005B1 (fr) | Nouvelles aminoalkylchromones, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
| IL81003A (en) | 5-aminoalkyl-beta-carboline derivatives and pharmaceutical compositions containing the same | |
| DK614989A (da) | Indolderivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem | |
| DE59004292D1 (de) | Renin-hemmende Aminooligohydroxy-Derivate. | |
| FI933928A0 (fi) | Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel | |
| DE69631104D1 (de) | 5,6,7,8-Tetrahydronaphto(2,3-b)furan- und indano(5,6-b)furan-amino-Verbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
| DE3782619D1 (de) | 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente. | |
| AU4930797A (en) | New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| ATE87004T1 (de) | Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln. | |
| NO159853C (no) | Analogifremgangsm te for fremstilling av terapeutisk aktive gamma-butyrolakton-derivater. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |